InNexus Announces new EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
Complete the form below to unlock access to ALL audio articles.
InNexus Biotechnology Inc. announces the development of a new antibody product from its DXL™ platform technology, DXL1218 (EGFR), for the prospective treatment of colorectal cancer.
"Recent experimental data suggests that DXL1218 (EGFR) is superior to competing commercialized products on the market, such as ERBITUX(R) (cetuximab), in terms of potency and efficacy," said Jeff Morhet, CEO and Chairman of InNexus. "I am very excited, as this latest development lends further support to the robustness and predictability of the DXL™ platform and the superiority of products from the platform over presently commercialized offerings."
Speaking on InNexus' announcement, Pablo Legorreta, Chief Executive Officer of Royalty Pharma said, "We are quite pleased with the rapid progress of our research partner InNexus. Jeff has had a vision for rapid product development based on DXL™ technology coupled with advanced in vivo studies and a significant regulatory strategy. We look forward to their continued rollout of products and performance."
